Respiratory medicine
-
Respiratory medicine · Sep 2019
Clinical TrialOutcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.
We explored the impact of FVC decline on subsequent FVC decline and mortality in the INPULSIS trials of nintedanib in patients with IPF and their open-label extension, INPULSIS-ON. ⋯ Decline in FVC did not predict FVC decline but was associated with mortality in patients with IPF.